T-Cell Depletion, Donor HSCT, and T-Cell Infusions in Treating Patients With Hematologic Cancer or Other Diseases
Status:
Unknown status
Trial end date:
0000-00-00
Target enrollment:
Participant gender:
Summary
RATIONALE: Giving chemotherapy and total-body irradiation before a donor peripheral blood
stem cell transplant helps stop the growth of cancer and abnormal cells and helps stop the
patient's immune system from rejecting the donor's stem cells. When stem cells from a donor
are infused into the patient they may help the patient's bone marrow make stem cells, red
blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor
can make an immune response against the body's normal cells. Removing the T cells from the
donor cells before transplant may stop this from happening. Giving an infusion of the
donor's T cells (donor lymphocyte infusion) after the transplant may help destroy any
remaining cancer cells (graft-versus-tumor effect).
PURPOSE: This phase II trial is studying T-cell depletion in donor stem cell transplant
followed by delayed T cell infusions in treating patients with hematologic cancer or other
disease.